On Nov 27, major Wall Street analysts update their ratings for $Exact Sciences (EXAS.US)$, with price targets ranging from $67 to $86.
TD Cowen analyst Daniel Brennan maintains with a buy rating, and adjusts the target price from $82 to $86.
Stifel analyst Daniel Arias maintains with a buy rating, and adjusts the target price from $82 to $67.
BTIG analyst Mark Massaro maintains with a buy rating, and adjusts the target price from $82 to $75.
Piper Sandler analyst David Westenberg maintains with a buy rating, and maintains the target price at $75.
Bernstein analyst Eve Burstein maintains with a buy rating, and adjusts the target price from $83 to $70.
Furthermore, according to the comprehensive report, the opinions of $Exact Sciences (EXAS.US)$'s main analysts recently are as follows:
Shares of Exact Sciences experienced an uptick, influenced by the announcement that the price for Cologuard Plus has been set at approximately $592 per test, marking a 16% increase over the first generation Cologuard. Analysts note that while a price adjustment was anticipated, the final rate and particulars of the adjustment were previously undetermined, and this recent update has contributed to reducing risk perceptions regarding the stock.
The final Medicare price for Cologuard Plus exceeded expectations, leading to an upward revision in estimates.
Here are the latest investment ratings and price targets for $Exact Sciences (EXAS.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月27日，多家華爾街大行更新了$精密科學 (EXAS.US)$的評級，目標價介於67美元至86美元。
TD Cowen分析師Daniel Brennan維持買入評級，並將目標價從82美元上調至86美元。
斯迪富分析師Daniel Arias維持買入評級，並將目標價從82美元下調至67美元。
BTIG分析師Mark Massaro維持買入評級，並將目標價從82美元下調至75美元。
派傑投資分析師David Westenberg維持買入評級，維持目標價75美元。
聯博集團分析師Eve Burstein維持買入評級，並將目標價從83美元下調至70美元。
此外，綜合報道，$精密科學 (EXAS.US)$近期主要分析師觀點如下：
以下爲今日6位分析師對$精密科學 (EXAS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
